EVALUATION IN MONKEYS OF CANDIDATE VACCINES FOR SIMIAN

恒河猴成功抵御猿猴感染的最新报道 免疫缺陷病毒(SIV)感染，使用灭活的全病毒 疫苗带来了希望，艾滋病疫苗有朝一日可能成为 现实(Desrosier等人和Murphey-Corb等人。(1989年)。非人 感染SIV或人类逆转录病毒HIV-2的灵长类动物代表 最有可能对糖尿病的发展做出重大贡献的动物模型 一种成功的艾滋病疫苗。这项提议的目标是建立 SIV疫苗评估股(SVEU)提供资源，以评估 部分或全部候选逆转录病毒疫苗的安全性和有效性 由国家过敏症和传染病研究所提供 (NIAID)。梅森研究所(MRI)将为现代非人类提供 非人灵长类畜牧业的灵长类设施和专业知识 医药。核磁共振成像将在美国进行科学的逆转录病毒研究计划 要求的病毒学、免疫学和临床病理学领域 NIAID工作说明书和任何后续修改。核磁共振可以感知 这是一种协作关系，在这种关系中，MRI研究团队将 为开展实验提供设施、服务和科学投入 具体涉及NIAID的疫苗合同目标。

Recent reports in rhesus monkeys of successful protection against simian immunodeficiency virus (SIV) infection, using inactivated whole virus vaccines, have provided hope that a vaccine against AIDS may someday be a reality (Desrosier et al. 1989 and Murphey-Corb et al. 1989). Non-human primates infected with SIV or the human retrovirus HIV-2 represent the animal models most likely to make major contributions to the development of a successful AIDS vaccine. The objective of this proposal is to establish a SIV Vaccine Evaluation Unit (SVEU) to provide a resource to assess the safety and efficacy, partial or complete, of candidate retroviral vaccines supplied by the National Institute of Allergy and Infectious Diseases (NIAID). Mason Research Institute (MRI) will provide modern non-human primate facilities and expertise in non-human primate animal husbandry and medicine. MRI will conduct a scientific retroviral research program in the fields of virology, immunology and clinical pathology as required by the NIAID Statement of Work and any subsequent modifications. MRI perceives this as a collaborative relationship in which the MRI research team will provide facilities, services, and scientific input to conduct experiments which specifically address vaccine contract goals of the NIAID.